76 related articles for article (PubMed ID: 11242605)
1. Achieving further glycemic control in type 2 diabetes mellitus.
Nichols GA; Glauber HS; Javor K; Brown JB
West J Med; 2000 Sep; 173(3):175-9. PubMed ID: 10986179
[TBL] [Abstract][Full Text] [Related]
2. Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus.
Goudswaard AN; Furlong NJ; Rutten GE; Stolk RP; Valk GD
Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD003418. PubMed ID: 15495054
[TBL] [Abstract][Full Text] [Related]
3. Metformin-Insulin versus Metformin-Sulfonylurea Combination Therapies in Type 2 Diabetes: A Comparative Study of Glycemic Control and Risk of Cardiovascular Diseases in Addis Ababa, Ethiopia.
Gebrie D; Manyazewal T; A Ejigu D; Makonnen E
Diabetes Metab Syndr Obes; 2021; 14():3345-3359. PubMed ID: 34335036
[TBL] [Abstract][Full Text] [Related]
4. Diabetes medication use and blood lactate level among participants with type 2 diabetes: the atherosclerosis risk in communities carotid MRI study.
Mongraw-Chaffin ML; Matsushita K; Brancati FL; Astor BC; Coresh J; Crawford SO; Schmidt MI; Hoogeveen RC; Ballantyne CM; Young JH
PLoS One; 2012; 7(12):e51237. PubMed ID: 23300538
[TBL] [Abstract][Full Text] [Related]
5. Should Metformin Continue as First-Line Pharmacotherapy for Patients With Type 2 Diabetes? Yes: Metformin Is Still the Best Choice.
Castelli G; Barlett SJ
Am Fam Physician; 2024 Mar; 109(3):200-201. PubMed ID: 38574204
[No Abstract] [Full Text] [Related]
6. [Recommendations for the pharmacological treatment of hyperglycemia in type 2 diabetes].
Menéndez Torre E; Lafita Tejedor FJ; Artola Menéndez S; Millán Núñez-Cortés J; Alonso García A; Puig Domingo M; García Solans JR; Alvarez Guisasola F; García Alegría J; Mediavilla Bravo J; Miranda Fernández-Santos C; Romero González R;
Aten Primaria; 2011 Apr; 43(4):202.e1-9. PubMed ID: 21382648
[No Abstract] [Full Text] [Related]
7. Causal inference in medical records and complementary systems pharmacology for metformin drug repurposing towards dementia.
Charpignon ML; Vakulenko-Lagun B; Zheng B; Magdamo C; Su B; Evans K; Rodriguez S; Sokolov A; Boswell S; Sheu YH; Somai M; Middleton L; Hyman BT; Betensky RA; Finkelstein SN; Welsch RE; Tzoulaki I; Blacker D; Das S; Albers MW
Nat Commun; 2022 Dec; 13(1):7652. PubMed ID: 36496454
[TBL] [Abstract][Full Text] [Related]
8. Assessment of glycemic control in patients with type 2 diabetes mellitus treated with metformin-sulfonylurea combination: Results of a multicenter, cross-sectional, observational study in Korea.
Kim SG; Hahm JR; Kim DK; Cho SR; Choi DS
J Diabetes Investig; 2015 May; 6(3):317-24. PubMed ID: 25969717
[TBL] [Abstract][Full Text] [Related]
9. The potential therapeutic effect of metformin in type 2 diabetic patients with severe COVID-19.
Al-Kuraishy HM; Al-Gareeb AI; El Kholy AA; El-Khateeb E; Alexiou A; Papadakis M; Elekhnawy E; Alsubaie N; Hamad RS; Batiha GE
Eur Rev Med Pharmacol Sci; 2023 Dec; 27(23):11445-11456. PubMed ID: 38095392
[TBL] [Abstract][Full Text] [Related]
10. Can technology improve adherence to long-term therapies?
Reach G
J Diabetes Sci Technol; 2009 May; 3(3):492-9. PubMed ID: 20144287
[TBL] [Abstract][Full Text] [Related]
11. Treatment for childhood type 2 diabetes.
Urakami T
Clin Pediatr Endocrinol; 2005; 14(1):1-9. PubMed ID: 24790303
[TBL] [Abstract][Full Text] [Related]
12. Sulfonylurea and neuroprotection: The bright side of the moon.
Hussien NR; Al-Naimi MS; Rasheed HA; Al-Kuraishy HM; Al-Gareeb AI
J Adv Pharm Technol Res; 2018; 9(4):120-123. PubMed ID: 30637228
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of pharmacokinetic drug interactions between gemigliptin (dipeptidylpeptidase-4 inhibitor) and glimepiride (sulfonylurea) in healthy volunteers.
Choi HY; Kim YH; Kim MJ; Lee SH; Bang K; Han S; Lim HS; Bae KS
Drugs R D; 2014 Sep; 14(3):165-76. PubMed ID: 24962635
[TBL] [Abstract][Full Text] [Related]
14. How long can insulin therapy be avoided in the patient with type 2 diabetes mellitus by use of a combination of metformin and a sulfonylurea?
Bell DS; Ovalle F
Endocr Pract; 2000; 6(4):293-5. PubMed ID: 11242605
[TBL] [Abstract][Full Text] [Related]
15. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial.
Yale JF; Valiquett TR; Ghazzi MN; Owens-Grillo JK; Whitcomb RW; Foyt HL
Ann Intern Med; 2001 May; 134(9 Pt 1):737-45. PubMed ID: 11329231
[TBL] [Abstract][Full Text] [Related]
16. Primary, secondary, tertiary, and quaternary treatment with troglitazone in type 2 diabetes mellitus in an outpatient clinical practice.
Hershon KS; Hershon PM
Endocr Pract; 2000; 6(1):20-5. PubMed ID: 11419922
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy.
Hollander P; Sugimoto D; Vlajnic A; Kilo C
J Diabetes Complications; 2015; 29(8):1266-71. PubMed ID: 26281972
[TBL] [Abstract][Full Text] [Related]
18. The use of insulin alone and in combination with oral agents in type 2 diabetes.
Buse JB
Prim Care; 1999 Dec; 26(4):931-50. PubMed ID: 10523468
[TBL] [Abstract][Full Text] [Related]
19. Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis.
Gross JL; Kramer CK; Leitão CB; Hawkins N; Viana LV; Schaan BD; Pinto LC; Rodrigues TC; Azevedo MJ;
Ann Intern Med; 2011 May; 154(10):672-9. PubMed ID: 21576535
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
